Table 2 Characteristics of CKRT circuits for COVID-19 patients and controls
From: Dialysis circuit clotting in critically ill patients with COVID-19 infection
| COVID-19 (n = 70) | Control (n = 22) | p-value | |
|---|---|---|---|
| Premature termination of dialysis due to clotting, n (%) | 45 (64) | 8 (36) | 0.02 |
| Circuit life, hours | 11 (5,18) | 12 (7,24) | 0.69 |
| CKRT modality, n (%) | |||
| CVVHDF | 56 (80) | 16 (73) | 0.53 |
| CVVH | 13 (19) | 6 (27) | |
| SCUF | 1 (1) | 0 (0) | |
| Systemic anticoagulation, n (%) | 8 (11) | 0 (0) | 1.00 |
| Anticoagulation during dialysis, n (%) | 24 (34) | 3 (14) | 0.10 |
| - Regional citrate anticoagulation | 21 (30) | 3 (14) | |
| - Heparin | 3 (4) | 0 (0) | |
| Systemic anticoagulation or anticoagulation during dialysis, n (%) | 29 (41) | 3 (14) | 0.02 |
| Prone positioning, n (%) | 12 (17) | 0 (0) | 0.03 |
| Vascular access, n (%) | |||
| - Femoral non-tunneled | 31 (44) | 20 (91) | < 0.05 |
| - Internal jugular non-tunneled | 39 (56) | 0 (0) | |
| - Internal jugular tunneled | 0 (0) | 2 (9) | |
| Blood flow rate, ml/min | 155.0 ± 13.6 | 151.4 ± 6.4 | 0.22 |
| Effluent dose, ml/kg/hr | 33.7 ± 6.9 | 27.3 ± 9.4 | < 0.05 |
| Filtration fraction, % | 14.8 ± 5.2 | 18.4 ± 5.2 | 0.01 |
| Hematocrit, % | 24 ± 3.9 | 34.8 ± 7.6 | < 0.05 |
| Platelets, × 109/L | 136 ± 76 | 134 ± 78 | 0.90 |
| INR | 1.2 (1, 1.4) | 1.3 (0.7, 1.9) | < 0.05 |
| aPTT, seconds | 36.0 (29.6, 42.4) | 35.1 (22.6, 47.6) | 0.84 |